Product Description
HSK42360 is a brain-permeable small molecule inhibitor developed independently by our company that targets BRAFV600 mutations. It is intended to be used clinically to treat advanced solid tumors with BRAFV600 mutations. Preclinical study results show that HSK42360 exhibits excellent anti-tumor efficacy in multiple solid tumor efficacy models with BRAFV600 mutations, and also exhibits good tolerability and a large safety window. It is a small molecule anti-tumor drug with great development potential and is expected to provide a new treatment option for patients with advanced solid tumors. (Sourced from: https://www.sohu.com/a/785521051_120988533)
Mechanisms of Action: BRAF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Haisco Pharmaceutical Group
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HSK42360-101 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-08-30 |